Second radiation course shows promise for returning brain tumors in kids
NCT ID NCT02125786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether surgery followed by a second course of radiation can help children and young adults (ages 1-21) whose ependymoma has returned after initial treatment. The combined radiation dose is higher than standard. Researchers will track how long the tumor stays under control, side effects, and use MRI/PET scans to predict response. Participants are followed for up to 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
68 people
The number who actually took part.
- Started
-
May 2014
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 21 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Progressive intracranial ependymoma after prior focal irradiation * Patients aged 1-21 years at the time of enrollment * Adequate performance status (ECOG \< 3) and research participant does not require mechanical ventilation * Interval from start of initial radiation therapy to enrollment \> 9 months Exclusion Criteria: * Prior craniospinal irradiation * Pregnant women are excluded from enrollment on this study because radiation therapy is an agent with the potential for teratogenic or abortifacient effects * Any patient with both metastatic ependymoma and age \< 3 years at the time of enrollment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ependymoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive gel aimed straight at childhood brain tumors
- Can an immune booster fight rare brain tumors?
- Can trained immune cells outsmart brain tumors?
- New platform trial takes on NF2 tumors with multiple drug strategies
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
- AI reads MRI scans to reveal hidden brain tumor types in children before surgery